Google
MGTX 株価分析 — Meiragtx Holdings PLC (Healthcare >> Biotechnology)
MGTX に関するよくある質問
MGTXのPER（株価収益率）は？
Meiragtx Holdings PLC（MGTX）は現在PER 72.92倍で取引されています。
MGTXのROE（自己資本利益率）は？
Meiragtx Holdings PLCのROEは207.35%です。
MGTXの配当利回りは？
Meiragtx Holdings PLCの配当利回りは0.00%です。
MGTXの品質スコア（Quality Score）は？
当社のAIはMGTXの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
MGTXは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
MGTXはどのセクターに属しますか？
Meiragtx Holdings PLCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
MGTX AI Analysis Summary
Our AI summary for MGTX: Meiragtx Holdings PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 72.92, ROE of 207.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 12.29
Price
0.41
(3.45%)
Day Change
|
|
|---|
MGTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 12.29 |
| PBV / Sector |
-18.93 / 44,022.72
|
| Earning Per Share | -1.35 |
| PE / Sector |
72.92 / 19.17
|
| PEG or PE/Growth / Sector |
-5.64 / 1.24
|
| Average 1M Daily Value |
7.73 M
|
| Average 1W Daily Value |
5.99 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:31 |
| Symbol | MGTX |
| Name | MEIRAGTX HOLDINGS PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 92.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,100.20 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 655 Third Avenue, New York, NY, United States, 10017
Phone: 646 860 7985
Website: https://www.meiragtx.com
Employees: 409
Sector: Healthcare >> Biotechnology
Description: MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
